Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium infantis CGMCC0460.1 + lactobacillus acidophilus CGMCC0460.2 + enterococcus faecalis CGMCC0460.3 + bacillus cereus CGMCC0460.4
- Development stage
- Phase 1
- Lead developer
- Hangzhou Grand Biologic Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intranasal
01
Overview
Combined live Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus cereus (CBLEB) is a probiotic drug widely used in China. [1] It is manufactured by Hangzhou Yuanda Biopharmaceutical Co., Ltd. and formulated from four specific bacterial strains: *Bifidobacterium infantis* CGMCC0460.1, *Lactobacillus acidophilus* CGMCC0460.2, *Enterococcus faecalis* CGMCC0460.3, and *Bacillus cereus* CGMCC0460.4. [3, 5] This biologic therapy is available in tablet, capsule, and powder forms. The drug's mechanism of action involves modulating the intestinal microbiota and the gut-brain axis, which leads to the regulation of inflammatory cytokines (NF-κB, IL-1β, TNF-α) and the restoration of intestinal barrier function. [12, 13] It is approved in China for treating various conditions, including post-stroke depression, digestive system diseases, and preventing adverse reactions from chemotherapy and radiation. [3, 7, 12] The drug holds National Drug Approval No. S20227006 in China. [7]
- Brand names
- Siliakang思连康
- Other names
- Combined live Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus cereusCBLEBCombined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, LiveBifidobacterium tetragonum tabletsBifidobacterium Quadruple Live Tablets
Beyond the preview
Go deeper on bifidobacterium infantis CGMCC0460.1 + lactobacillus acidophilus CGMCC0460.2 + enterococcus faecalis CGMCC0460.3 + bacillus cereus CGMCC0460.4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium infantis CGMCC0460.1 + lactobacillus acidophilus CGMCC0460.2 + enterococcus faecalis CGMCC0460.3 + bacillus cereus CGMCC0460.4.